What is the price target for Agenus stock?
The average twelve-month price target for Agenus is $11.00 with a high price target of $11.00 and a low price target of $11.00. Learn more Do Wall Street analysts like Agenus more than its competitors? Analysts like Agenus stock more than the stock of other Medical companies.
What is the price target for Agen Inc (Agen)?
The high price target for AGEN is $6.00 and the low price target for AGEN is $6.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
What was the 52-week low for Agenus stock?
The low in the last 52 weeks of Agenus stock was 1.26. According to the current price, Agenus is 204.78% away from the 52-week low. What was the 52-week high for Agenus stock? The high in the last 52 weeks of Agenus stock was 6.79. According to the current price, Agenus is 37.88% away from the 52-week high.
What are analysts'price targets for Agenus'stock?
2 Wall Street analysts have issued 12-month price targets for Agenus' stock. Their forecasts range from $11.00 to $12.00. On average, they anticipate Agenus' share price to reach $11.50 in the next year. This suggests a possible upside of 221.2% from the stock's current price.
Is AGEN a good stock to buy?
Agenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Who is AGEN stock?
A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.
Why is AGEN stock going up?
A strong agreement among sell-side analysts covering AGEN in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 1.2% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
What kind of company is AGEN?
immuno-oncology companyAgenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Is Spectrum Pharmaceuticals a good investment?
Spectrum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
What does agenus company do?
Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.
Is agenus a good stock to buy 2021?
The 2 analysts offering 12-month price forecasts for Agenus Inc have a median target of 7.50, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +161.32% increase from the last price of 2.87.
Who owns agenus?
Top 10 Owners of Agenus IncStockholderStakeShares ownedThe Vanguard Group, Inc.6.30%17,830,122SSgA Funds Management, Inc.6.28%17,758,624BlackRock Fund Advisors5.22%14,770,596Deep Track Capital LP4.95%13,998,4916 more rows
Who is the founder of agenus?
Garo H. ArmenAgenus / FounderGaro H. Armen is an American-Armenian scientist and philanthropist. He is the founder and chairman of the Children of Armenia Fund, as well as co-founder and CEO of Agenus, Inc. Wikipedia
Should I buy or sell Agenus stock right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 2...
What is Agenus' stock price forecast for 2022?
2 equities research analysts have issued 12 month price objectives for Agenus' stock. Their forecasts range from $8.00 to $14.00. On average, they...
How has Agenus' stock price performed in 2022?
Agenus' stock was trading at $3.22 at the start of the year. Since then, AGEN stock has decreased by 54.7% and is now trading at $1.46. View the b...
When is Agenus' next earnings date?
Agenus is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Agenus .
How were Agenus' earnings last quarter?
Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported ($0.19) EPS for the quarte...
Who are Agenus' key executives?
Agenus' management team includes the following people: Dr. Garo H. Armen Ph.D. , Founder, Exec. Chairman & CEO (Age 69, Pay $1.07M) Ms. Christin...
What is Garo H. Armen's approval rating as Agenus' CEO?
2 employees have rated Agenus CEO Garo H. Armen on Glassdoor.com . Garo H. Armen has an approval rating of 56% among Agenus' employees. This puts...
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron Pharmaceuti...
What other stocks do shareholders of Agenus own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG) , Exelixis (EX...
Nasdaq Capital Market (Nasdaq)
Environmental, Social, and Governance Rating
A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Agenus (NASDAQ:AGEN) Price Target and Consensus Rating
A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Agenus (NASDAQ:AGEN) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
